PMID- 23563279
OWN - NLM
STAT- MEDLINE
DCOM- 20131212
LR  - 20181202
IS  - 1879-016X (Electronic)
IS  - 0163-7258 (Linking)
VI  - 139
IP  - 1
DP  - 2013 Jul
TI  - Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the 
      treatment of type 2 diabetes: preclinical and clinical data.
PG  - 51-9
LID - S0163-7258(13)00082-X [pii]
LID - 10.1016/j.pharmthera.2013.04.003 [doi]
AB  - Sodium-glucose cotransporter-2 (SGLT2) is expressed in the proximal tubules of 
      the kidneys and plays a key role in renal glucose reabsorption. A novel class of 
      antidiabetic medications, SGLT2-selective inhibitors attempt to improve glycemic 
      control in diabetics by preventing glucose from being reabsorbed through SGLT2 
      and re-entering circulation. Ipragliflozin is an SGLT2 inhibitor in Phase 3 
      clinical development for the treatment of type 2 diabetes mellitus (T2DM). In 
      this review, we summarize recent animal and human studies on ipragliflozin and 
      other SGLT2 inhibitors including dapagliflozin, canagliflozin, empagliflozin, 
      tofogliflozin, and luseogliflozin. These agents all show potent and selective 
      SGLT2 inhibition in vitro and reduce blood glucose levels and HbA1c in both 
      diabetic animal models and patients with T2DM. SGLT2 inhibitors offer several 
      advantages over other classes of hypoglycemic agents. Due to their 
      insulin-independent mode of action, SGLT2 inhibitors provide steady glucose 
      control without major risk for hypoglycemia and may also reverse beta-cell 
      dysfunction and insulin resistance. Other favorable effects of SGLT2 inhibitors 
      include a reduction in both body weight and blood pressure. SGLT2 inhibitors are 
      safe and well tolerated and can easily be combined with other classes of 
      antidiabetic medications to achieve tighter glycemic control. The long-term 
      safety and efficacy of these agents are under evaluation.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Kurosaki, Eiji
AU  - Kurosaki E
AD  - Astellas Pharma, Inc., Ibaraki, Japan. eiji.kurosaki@astellas.com
FAU - Ogasawara, Hideaki
AU  - Ogasawara H
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130404
PL  - England
TA  - Pharmacol Ther
JT  - Pharmacology & therapeutics
JID - 7905840
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Thiophenes)
RN  - 3N2N8OOR7X (ipragliflozin)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism/physiopathology
MH  - Glucose/metabolism
MH  - Glucosides/pharmacology/*therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/*therapeutic use
MH  - Kidney/metabolism
MH  - *Sodium-Glucose Transporter 2 Inhibitors
MH  - Thiophenes/pharmacology/*therapeutic use
EDAT- 2013/04/09 06:00
MHDA- 2013/12/18 06:00
CRDT- 2013/04/09 06:00
PHST- 2013/02/28 00:00 [received]
PHST- 2013/03/01 00:00 [accepted]
PHST- 2013/04/09 06:00 [entrez]
PHST- 2013/04/09 06:00 [pubmed]
PHST- 2013/12/18 06:00 [medline]
AID - S0163-7258(13)00082-X [pii]
AID - 10.1016/j.pharmthera.2013.04.003 [doi]
PST - ppublish
SO  - Pharmacol Ther. 2013 Jul;139(1):51-9. doi: 10.1016/j.pharmthera.2013.04.003. Epub 
      2013 Apr 4.